DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Hard-to-Treat cancers: adding a pill to standard chemo
Disease control OngoingThis study is testing if adding a pill called venetoclax to standard chemotherapy works better than chemotherapy alone for people with aggressive types of B-cell lymphoma. The goal is to better control the cancer and keep it from coming back. About 363 adults with specific, hard-…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Double-Punch combo trial aims to boost Cancer-Killing power
Disease control OngoingThis study is testing whether adding a pill called acalabrutinib makes a powerful cell therapy (CAR-T) work better and safer for people with certain aggressive B-cell lymphomas. The trial enrolled 23 adults to see if the combination is safe and can help control the cancer. Resear…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Scientists test new arsenal against stubborn blood cancer
Disease control TerminatedThis early-stage study is testing a new combination of three drugs for adults with an aggressive type of lymphoma that has come back or not responded to previous treatments. The main goal is to find the safest and most effective dose of these drugs when used together. Researchers…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New pill aims to boost cancer fight for seniors
Disease control TerminatedThis study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Tiny chip in blood could spot cancer return sooner
Knowledge-focused OngoingThis study is testing a new nanochip technology that analyzes blood samples to monitor how well treatment is working and to try to detect if cancer returns earlier in patients with diffuse large B-cell lymphoma. Researchers will collect blood from 73 patients at diagnosis, during…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:41 UTC